

# CITATION REPORT

List of articles citing

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy

DOI: 10.1007/s00415-005-0934-5

Journal of Neurology, 2006, 253, 98-108.

**Source:** <https://exaly.com/paper-pdf/40663027/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
437	Graves' disease after treatment with alemtuzumab for multiple sclerosis. <b>2015</b> , 14, 148-53		15
436	The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. <b>2006</b> , 52, 61-76		583
435	Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design. <b>2006</b> , 19, 255-9		28
434	The basis for treatment in multiple sclerosis. <b>2006</b> , 183, 41-7		11
433	Immunoglobulins--basic considerations. <i>Journal of Neurology</i> , <b>2006</b> , 253 Suppl 5, V9-17	5.5	41
432	Rationale and experience with combination therapies in multiple sclerosis. <i>Journal of Neurology</i> , <b>2006</b> , 253, vi45-vi51	5.5	3
431	Stem cell therapy in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2006</b> , 12, 677-8	5	6
430	B-cell targeting: a novel approach to immune intervention today and tomorrow. <b>2007</b> , 7, 1287-99		30
429	Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. <b>2007</b> , 8, 1103-16		17
428	Neurofascin as a novel target for autoantibody-mediated axonal injury. <b>2007</b> , 204, 2363-72		315
427	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. <i>Multiple Sclerosis Journal</i> , <b>2007</b> , 13, 1068-70	5	45
426	New insights into adaptive immunity in chronic neuroinflammation. <b>2007</b> , 96, 1-40		39
425	Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. <b>2007</b> , 83, 1429-34		30
424	ADVANCES IN THE NEUROPATHOLOGY OF MULTIPLE SCLEROSIS. <b>2007</b> , 13, 86-116		
423	DISEASE-MODIFYING THERAPIES. <b>2007</b> , 13, 144-180		
422	Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies. <b>2007</b> , 203, 1-4		16
421	T cell immunomodulation--the Holy Grail of therapeutic tolerance. <b>2007</b> , 7, 418-25		20

420	New therapeutic approaches for multiple sclerosis. <b>2007</b> , 58, 417-32	40
419	Multiple sclerosis: is there neurodegeneration independent from inflammation?. <b>2007</b> , 259, 3-6	81
418	The gap between effect of drugs and effectiveness of treatments. <b>2007</b> , 259, 128-32	4
417	Sodium channel blockers as neuroprotectants in neuroinflammatory disease: a double-edged sword. <b>2007</b> , 62, 3-5	5
416	Toward the development of rational therapies in multiple sclerosis: what is on the horizon?. <b>2007</b> , 62, 314-26	53
415	Emerging therapies for multiple sclerosis. <b>2007</b> , 4, 676-92	23
414	Cannabinoid control of neuroinflammation related to multiple sclerosis. <b>2007</b> , 152, 649-54	48
413	The immunopathology of multiple sclerosis: an overview. <b>2007</b> , 17, 210-8	802
412	The immunological basis for treatment of multiple sclerosis. <b>2007</b> , 66, 374-82	19
411	Immunopathogenesis of multiple sclerosis: concepts and controversies. <b>2007</b> , 187, 39-45	22
410	The interplay between inflammation and neurodegeneration in CNS disease. <b>2007</b> , 184, 4-16	74
409	Should targeting immunosuppression, immunoregulation or remyelination be used to treat inflammatory neuropathies?. <b>2007</b> , 190, 3-4	
408	Autoimmune modulation of astrocyte-mediated homeostasis. <b>2007</b> , 9, 1-16	7
407	Current treatment options in multiple sclerosis. <b>2007</b> , 9, 176-86	9
406	Successful treatment of cancer-associated retinopathy with alemtuzumab. <b>2007</b> , 83, 295-302	47
405	Multiple sclerosis therapy: an update on recently finished trials. <i>Journal of Neurology</i> , <b>2007</b> , 254, 1473-90,5	5
404	New concepts on progressive multiple sclerosis. <b>2007</b> , 7, 239-44	49
403	New developments in understanding and treating neuroinflammation. <b>2008</b> , 86, 975-85	38

402	Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. <i>Journal of Neurology</i> , <b>2008</b> , 255, 1449-63	5.5	173
401	Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. <i>Journal of Neurology</i> , <b>2008</b> , 255, 231-8	5.5	73
400	Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study. <i>Journal of Neurology</i> , <b>2008</b> , 255, 1378-83	5.5	24
399	Rationale for early intervention with immunomodulatory treatments. <i>Journal of Neurology</i> , <b>2008</b> , 255 Suppl 1, 37-43	5.5	71
398	Monoclonal antibodies in the therapy of multiple sclerosis: an overview. <i>Journal of Neurology</i> , <b>2008</b> , 255 Suppl 6, 28-35	5.5	18
397	Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. <b>2008</b> , 75, 157-67		17
396	Intravenous therapy for the treatment of multiple sclerosis. <b>2008</b> , 8, 15-20		1
395	T cells in amyotrophic lateral sclerosis. <b>2008</b> , 15, 360-6		61
394	Getting specific: monoclonal antibodies in multiple sclerosis. <b>2008</b> , 7, 538-47		66
393	Autologous haematopoietic stem-cell transplantation in multiple sclerosis. <b>2008</b> , 7, 626-36		160
392	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. <b>2008</b> , 193, 120-9		82
391	Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. <b>2008</b> , 196, 159-65		49
390	Disease-modifying agents for multiple sclerosis: recent advances and future prospects. <b>2008</b> , 68, 2445-68		50
389	Interferon-beta1b for the treatment of multiple sclerosis. <b>2008</b> , 4, 1111-7		4
388	Advances in multiple Sclerosis and Experimental Demyelinating Diseases. <b>2008</b> ,		3
387	The pathologic substrate of magnetic resonance alterations in multiple sclerosis. <b>2008</b> , 18, 563-76, ix		72
386	Identification and development of new therapeutics for multiple sclerosis. <b>2008</b> , 29, 558-65		52
385	Multiple sclerosis. <b>2008</b> , 372, 1502-17		3360

384	Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. <b>2008</b> , 274, 48-53		194
383	Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. <b>2008</b> , 79, 52-6		91
382	Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 22-34	5	74
381	Protecting axons in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2008</b> , 14, 1013-25	5	33
380	Autologous HSCT for advanced MS: is the glass half-empty or really half-full?. <b>2008</b> , 131, e89; author reply e90		4
379	Innovative monoclonal antibody therapies in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2008</b> , 1, 43-52	6.6	19
378	Campath-1H treatment of multiple sclerosis. <b>2008</b> , 5, 27-31		30
377	Hormonal influences in multiple sclerosis. <b>2008</b> , 318, 267-311		15
376	Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. <b>2008</b> , 79, 1137-43		42
375	Treating multiple sclerosis with monoclonal antibodies. <b>2008</b> , 8, 433-55		30
374	More on anti-glomerular basement membrane disease after alemtuzumab. <b>2008</b> , 359, 2501-2; author reply 2502		1
373	Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. <b>2008</b> , 359, 1786-801		769
372	Future research directions in multiple sclerosis therapies. <b>2008</b> , 28, 121-7		10
371	Autologous hemopoietic stem cell transplantation for multiple sclerosis: is it worthwhile?. <b>2008</b> , 41, 601-10		9
370	Pharmacogenomics in multiple sclerosis: getting the right medicine to the right patient. <b>2008</b> , 5, 623-629		1
369	Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. <b>2008</b> , 118, 1532-43		167
368	The endocannabinoid system and multiple sclerosis. <b>2008</b> , 14, 2326-36		46
367	New approaches of B-cell-directed therapy: beyond rituximab. <b>2008</b> , 20, 263-8		68

366	Multiple sclerosis: immunopathogenesis and controversies in defining the cause. <b>2008</b> , 21, 271-8		34
365	Multiple sclerosis: new treatment trials and emerging therapeutic targets. <b>2008</b> , 21, 261-71		22
364	Current and future directions in MS management: key considerations for managed care pharmacists. <b>2009</b> , 15, S2-15; quiz S16-7		8
363	Emerging therapies for relapsing multiple sclerosis. <b>2009</b> , 66, 821-8		24
362	Monoclonal antibodies in multiple sclerosis treatment: current and future steps. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2009</b> , 2, 195-203	6.6	15
361	Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies. <b>2009</b> , 1, 403-23		4
360	Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype. <b>2009</b> , 5, 300-2		5
359	Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2009</b> , 2, 50-61	6.6	45
358	Examination of the role of MRI in multiple sclerosis: a problem orientated approach. <b>2010</b> , 51, 287-301		
357	Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. <b>2009</b> , 132, 1536-44		147
356	Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. <b>2009</b> , 57, 418-23		10
355	Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. <b>2009</b> , 72, 402-9		234
354	Promising treatments of tomorrow for multiple sclerosis. <b>2009</b> , 12, 283-90		4
353	Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach. <b>2009</b> , 12, 254-63		11
352	Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. <b>2009</b> , 8, 280-91		447
351	Current treatments of chronic immune-mediated demyelinating polyneuropathies. <b>2009</b> , 39, 563-78		59
350	[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis]. <b>2009</b> , 80, 468-74		0
349	Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. <b>2009</b> , 128, 260-70		239

348	Autoimmune T cell responses in the central nervous system. <b>2009</b> , 9, 393-407	708
347	Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. <b>2009</b> , 14, 118-24	50
346	Melanoma following treatment with alemtuzumab for multiple sclerosis. <b>2009</b> , 16, e70-1	25
345	Sex Differences in Autoimmune Diseases. <b>2009</b> , 2259-2291	1
344	Predicting and preventing the future: actively managing multiple sclerosis. <b>2009</b> , 9, 133-43, discussion 144	11
343	Concepts of induction and escalation therapy in multiple sclerosis. <b>2009</b> , 277 Suppl 1, S42-5	41
342	Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. <b>2009</b> , 282, 112-9	69
341	Estrogen and testosterone therapies in multiple sclerosis. <b>2009</b> , 175, 239-51	131
340	Cannabidiol: a promising drug for neurodegenerative disorders?. <b>2009</b> , 15, 65-75	152
339	Impact of multiple sclerosis relapses on progression diminishes with time. <b>2009</b> , 73, 1616-23	170
338	Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. <b>2009</b> , 87, 125-32	40
337	5. Autoimmunity and Allergy of Central Nerve. <b>2009</b> , 98, 571-576	
336	Multiple sclerosis: clinical features, pathophysiology, neuroimaging and future therapies. <b>2009</b> , 4, 229-246	7
335	Multiple Sclerosis and Demyelinating Diseases. 411-447	3
334	Emerging multiple sclerosis disease-modifying therapies. <b>2009</b> , 22, 226-32	18
333	Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies. <b>2010</b> , 8, 305-15	76
332	Chemotherapeutics in the treatment of multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2010</b> , 3, 277-91	6.6 25
331	Emerging therapies in relapsing-remitting multiple sclerosis. <b>2010</b> , 5, 179-88	11

330	Alemtuzumab for the treatment of multiple sclerosis. <b>2010</b> , 5, 177-188		
329	Current and emerging multiple sclerosis therapeutics. <b>2010</b> , 16, 58-77		5
328	[Therapeutic monoclonal antibodies in clinical neurology]. <b>2010</b> , 81, 753-64; quiz 765-6		4
327	Intrathecal methotrexate treatment in multiple sclerosis. <i>Journal of Neurology</i> , <b>2010</b> , 257, 1806-11	5.5	22
326	B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. <b>2010</b> , 30, 99-105		180
325	Pharmacologic agents for pediatric neuroimmune disorders. <b>2010</b> , 17, 245-53		6
324	Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation. <b>2010</b> , 1183, 222-36		22
323	Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. <b>2010</b> , 6, 153-72		14
322	The physiopathology of multiple sclerosis. 8-21		1
321	Emerging Therapies for the Management of Multiple Sclerosis. <b>2010</b> , 2, CMT.S2213		1
320	Multiple sclerosis: a practical overview for clinicians. <b>2010</b> , 95, 79-104		60
319	Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 1490-9	5	22
318	Evidence for a two-stage disability progression in multiple sclerosis. <b>2010</b> , 133, 1900-13		386
317	Immunomodulatory drug treatment in multiple sclerosis. <b>2010</b> , 10, 1423-36		10
316	Treating multiple sclerosis with monoclonal antibodies: a 2010 update. <b>2010</b> , 10, 791-809		38
315	A novel strategy to reduce the immunogenicity of biological therapies. <b>2010</b> , 185, 763-8		58
314	Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges. <b>2010</b> , 2, 670-81		21
313	Predicting a window of therapeutic opportunity in multiple sclerosis. <b>2010</b> , 133, 1863-5		6



312	Monoclonal antibodies in MS: mechanisms of action. <b>2010</b> , 74 Suppl 1, S31-40	89
311	Have we overestimated the benefit of human(ized) antibodies?. <b>2010</b> , 2, 682-94	67
310	Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. <b>2010</b> , 10, 1789-97	29
309	Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. <b>2010</b> , 133, 2232-47	131
308	Beneficial brain autoimmunity?. <b>2010</b> , 133, 2182-4	4
307	Therapy of MS. <b>2010</b> , 112, 365-85	74
306	Review of neurologic diseases for the urologist. <b>2010</b> , 37, 517-26	24
305	Future neuroprotective strategies. <b>2010</b> , 225, 40-7	9
304	New treatment strategies in multiple sclerosis. <b>2010</b> , 225, 34-9	31
303	Tolerance: an overview and perspectives. <b>2010</b> , 6, 569-76	35
302	Molecular Basis of Multiple Sclerosis. <b>2010</b> ,	1
301	Importance of age at diagnosis in multiple sclerosis. <b>2010</b> , 10, 341-2	2
300	Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?. <b>2010</b> , 6, 319-21	4
299	Current and future role of interferon beta in the therapy of multiple sclerosis. <b>2010</b> , 30, 715-26	14
298	Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. <b>2010</b> , 51, 1293-304	60
297	Rituximab for secondary progressive multiple sclerosis: a case series. <b>2011</b> , 25, 607-13	17
296	Promising emerging therapies for multiple sclerosis. <b>2011</b> , 29, 435-48	8
295	Monoclonal antibodies in development in multiple sclerosis. <b>2011</b> , 26, 556-562	

294	A new treatment era in multiple sclerosis: clinical applications of new concepts. <b>2011</b> , 306, 170-2	3
293	Clinical Neuroimmunology. <b>2011</b> ,	
292	Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis. <b>2011</b> , 178, 1770-81	27
291	Genetics of multiple sclerosis. <b>2011</b> , 1812, 194-201	25
290	Measures of acute and chronic lesions visualized by conventional magnetic resonance imaging. 91-111	
289	Measures of neurological impairment and disability in multiple sclerosis. 56-64	
288	Interferon beta to treat multiple sclerosis. 300-314	
287	Alemtuzumab to treat multiple sclerosis. 393-398	
286	Recognition of a high affinity MHC class I-restricted epitope of myelin oligodendrocyte glycoprotein by CD8+ T cells derived from autoantigen-deficient mice. <b>2011</b> , 2, 17	6
285	The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis. <b>2011</b> , 6, e19138	26
284	THE ANTIBODY PROBLEM AND THE GENERATION OF MONOCLONAL ANTIBODIES. <b>2011</b> , 197-215	
283	Immune tolerance in multiple sclerosis. <b>2011</b> , 241, 228-40	67
282	[Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis]. <b>2011</b> , 26, 556-62	
281	A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. <b>2011</b> , 230, 1-9	60
280	More to come: humoral immune responses in MS. <b>2011</b> , 240-241, 13-21	5
279	Alemtuzumab versus interferon $\beta$ 1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. <b>2011</b> , 10, 338-48	108
278	The molecular basis of neurodegeneration in multiple sclerosis. <b>2011</b> , 585, 3715-23	201
277	Treatment of multiple sclerosis: current concepts and future perspectives. <i>Journal of Neurology</i> , <b>2011</b> , 258, 1747-62	5.5 43

276	Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. <b>2011</b> , 33, 341-51	19
275	Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis. <b>2011</b> , 8, 643-9	13
274	Sex differences in autoimmune diseases. <b>2011</b> , 2, 1	130
273	The interleukin-7 receptor $\alpha$ chain contributes to altered homeostasis of regulatory T cells in multiple sclerosis. <b>2011</b> , 41, 845-53	32
272	Was gibt es Neues bei der Multiplen Sklerose?. <b>2011</b> , 38, 190-202	1
271	Novel therapeutic approaches to autoimmune demyelinating disorders. <b>2011</b> , 17, 3191-201	2
270	Therapeutic application of monoclonal antibodies in multiple sclerosis: focus on alemtuzumab. <b>2011</b> , 33	
269	Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis. <b>2011</b> , 3, 235-257	
268	Alemtuzumab in Multiple Sclerosis. <b>2011</b> , 48, 79-82	1
267	Multipl Skleroz Patogenezinde B Hücrelerinin Rolü ve B Hücre Karşı Monoklonal Antikor Tedavileri. <b>2011</b> , 48, 73-78	
266	Thyroid dysfunction from antineoplastic agents. <b>2011</b> , 103, 1572-87	108
265	Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. <b>2011</b> , 77, 573-9	159
264	<sup>18</sup> F-FDG PET detects inflammatory infiltrates in spinal cord experimental autoimmune encephalomyelitis lesions. <b>2012</b> , 53, 1269-76	30
263	Benefits versus risks of latest therapies in multiple sclerosis: a perspective review. <b>2012</b> , 3, 291-303	2
262	Monoclonal antibodies in the treatment of neuroimmunological diseases. <b>2012</b> , 18, 4498-507	9
261	Radiologisch isoliertes Syndrom: Verlauf und Empfehlungen zum klinischen Management. <b>2012</b> , 39, S6-S9	
260	Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. <b>2012</b> , 12, 335-41	65
259	There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - Yes. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 927-9	5 1

258	Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. <b>2012</b> , 4, 117ra7		260
257	Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1197-9	5	5
256	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. <b>2012</b> , 83, 298-304		148
255	Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. <b>2012</b> , 18, 209-19		45
254	Immune therapy of multiple sclerosis--future strategies. <b>2012</b> , 18, 4489-97		22
253	Current issues in vaccines for adult patients with hematologic malignancies. <b>2012</b> , 10, 1447-54; quiz 1454		11
252	Neurodegeneration and neuroprotection in multiple sclerosis. <b>2012</b> , 18, 4471-4		10
251	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <b>2012</b> , 380, 1819-28		834
250	Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. <b>2012</b> , 8, 1817-28		122
249	What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?. <b>2012</b> , 13, 12665-709		29
248	Alemtuzumab more effective than interferon $\beta$ 1a at 5-year follow-up of CAMMS223 clinical trial. <b>2012</b> , 78, 1069-78		204
247	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <b>2012</b> , 380, 1829-39		827
246	The role of B cells in solid organ transplantation. <b>2012</b> , 24, 96-108		28
245	Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. <b>2012</b> , 26, 11-37		28
244	Glial and Axonal Pathology in Multiple Sclerosis. <b>2012</b> ,		
243	Emerging disease-modifying therapies in multiple sclerosis. <b>2012</b> , 14, 256-63		18
242	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 835-42	5	95
241	[Alemtuzumab: a further option for treatment of multiple sclerosis]. <b>2012</b> , 83, 487-501		1

240	New and emerging disease modifying therapies for multiple sclerosis. <b>2012</b> , 1247, 117-37	38
239	A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. <b>2012</b> , 19, 307-11	32
238	Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. <b>2012</b> , 142, 25-30	52
237	Immune modulating peptides for the treatment and suppression of multiple sclerosis. <b>2012</b> , 144, 127-38	25
236	Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. <b>2012</b> , 123, 247-58	53
235	Monoclonal antibodies in neuroinflammatory diseases. <b>2013</b> , 13, 831-46	12
234	Progressive Multiple Sclerosis. <b>2013</b> ,	
233	Multiple sclerosis: Prospects and promise. <b>2013</b> , 74, 317-27	143
232	[Is MRI monitoring useful in clinical practice in patients with multiple sclerosis? No]. <b>2013</b> , 169, 864-8	0
231	Multiple Sclerosis Immunology. <b>2013</b> ,	4
230	Monoclonal antibodies as disease modifying therapy in multiple sclerosis. <b>2013</b> , 13, 390	6
229	Influenza vaccination in oncology patients. <b>2013</b> , 15, 486-90	9
228	The outlook for alemtuzumab in multiple sclerosis. <b>2013</b> , 27, 181-9	6
227	The benefits and risks of alemtuzumab in multiple sclerosis. <b>2013</b> , 9, 189-91	4
226	Thyroid dysfunction as an unintended side effect of anticancer drugs. <b>2013</b> , 23, 1345-66	76
225	Alemtuzumab therapy for multiple sclerosis. <b>2013</b> , 10, 29-33	58
224	ECTRIMS 2012: Treatment highlights. <i>Multiple Sclerosis and Related Disorders</i> , <b>2013</b> , 2, 68-72	4
223	Primary progressive multiple sclerosis: progress and challenges. <b>2013</b> , 84, 1100-6	44

222	Treating multiple sclerosis with monoclonal antibodies: a 2013 update. <b>2013</b> , 13, 313-35		40
221	MS as a gateway disease. <b>2013</b> , 333, 73-5		1
220	Induction therapy for patients with multiple sclerosis: why? When? How?. <b>2013</b> , 27, 403-9		33
219	Modeling the heterogeneity of multiple sclerosis in animals. <b>2013</b> , 34, 410-22		128
218	Drugs in development for relapsing multiple sclerosis. <b>2013</b> , 73, 625-50		42
217	Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2013</b> , 2, 60-3	4	26
216	Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. <b>2013</b> , 80, 55-61		53
215	Alemtuzumab treatment of multiple sclerosis. <b>2013</b> , 33, 66-73		24
214	Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. <b>2013</b> , 2013, 963748		59
213	Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1302-9	5	12
212	First use of alemtuzumab in Balo's concentric sclerosis: a case report. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1673-5	5	9
211	Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. <b>2013</b> , 4, 97-103		11
210	Diffusion tensor MRI as a biomarker in axonal and myelin damage. <b>2013</b> , 5, 427-440		161
209	Natural history of multiple sclerosis symptoms. <i>International Journal of MS Care</i> , <b>2013</b> , 15, 146-58	2.3	223
208	Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. <b>2013</b> , 7, 131-8		25
207	Alemtuzumab in the treatment of multiple sclerosis. <b>2014</b> , 7, 19-27		7
206	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 471-80	5	93
205	Biomarkers of treatment response in multiple sclerosis. <b>2014</b> , 14, 165-72		8

204	Immunological Tolerance. <b>2014,</b>	3
203	Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO. <b>2014,</b> 1, e34	42
202	Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. <b>2014,</b> 6, 249-59	16
201	Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. <b>2014,</b> 176, 135-48	8
200	Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. <b>2014,</b> 141, 123-31	51
199	Multiple sclerosis treatment and infectious issues: update 2013. <b>2014,</b> 175, 425-38	25
198	Current evaluation of alemtuzumab in multiple sclerosis. <b>2014,</b> 14, 127-35	8
197	Cell therapy for multiple sclerosis: a new hope. <b>2014,</b> 7, hzu014-hzu014	2
196	Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. <b>2014,</b> 99, 80-9	97
195	Sound Lateralization Test Distinguishes Unimpaired MS Patients from Healthy Controls. <b>2014,</b> 2014, 462043	0
194	How implementation of systems biology into clinical trials accelerates understanding of diseases. <b>2014,</b> 5, 102	26
193	Mode of action and clinical studies with alemtuzumab. <b>2014,</b> 262 Pt A, 37-43	43
192	Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists. <b>2014,</b> 21, 1847-56	17
191	The Potential of Human Amnion Epithelial Cells as an Immunomodulatory and Neuroregenerative Treatment for Multiple Sclerosis. <b>2014,</b> 231-242	4
190	Pathology of multiple sclerosis and related inflammatory demyelinating diseases. <b>2014,</b> 122, 15-58	179
189	Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. <b>2014,</b> 82, 2158-64	44
188	Alemtuzumab for multiple sclerosis. <b>2014,</b>	1
187	Disease-modifying agents in multiple sclerosis. <b>2014,</b> 122, 465-501	9

186	Alemtuzumab (Lemtrada, MabCampath)1. <b>2014</b> , 1323-1374		
185	Perinatal Stem Cells. <b>2014</b> ,		3
184	Cerebrospinal fluid analysis. <b>2014</b> , 122, 681-702		24
183	Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis. <b>2014</b> , 74, 489-504		13
182	Disease modification in multiple sclerosis: an update. <b>2014</b> , 14, 6-13		8
181	Alemtuzumab and multiple sclerosis: is it safe?. <b>2014</b> , 83, 17-8		3
180	Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. <b>2014</b> , 10, 1281-91		11
179	Alemtuzumab: the advantages and challenges of a novel therapy in MS. <b>2014</b> , 83, 87-97		35
178	Drug safety evaluation of alemtuzumab for multiple sclerosis. <b>2014</b> , 13, 1115-24		8
177	Mechanism of multiple sclerosis based on the clinical trial results of molecular targeted therapy. <b>2014</b> , 5, 6-15		1
176	Neurodegeneration in multiple sclerosis is a process separate from inflammation: No. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1628-31	5	13
175	Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis. <b>2015</b> , 28, 230-6		6
174	Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis. <b>2015</b> , 11, 1221-9		6
173	Alemtuzumab for the treatment of multiple sclerosis. <b>2015</b> , 11, 525-34		14
172	Monoclonal Antibodies for Multiple Sclerosis Treatment. <b>2015</b> , 28, 640-51		1
171	A new era in the treatment of multiple sclerosis. <b>2015</b> , 203, 139-41, 141e.1		9
170	Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. <b>2015</b> , 16, 16414-39		115
169	Activation of endogenous neural stem cells for multiple sclerosis therapy. <b>2014</b> , 8, 454		19



168	Timing is everything in the treatment of multiple sclerosis. <b>2015</b> , 2015,		0
167	Aggressive multiple sclerosis: proposed definition and treatment algorithm. <b>2015</b> , 11, 379-89		82
166	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. <b>2015</b> , 15, 251-68		4
165	Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. <b>2015</b> , 84, 981-8		155
164	Multiple Sclerosis. <b>2015</b> , 1001-1014		6
163	Pathophysiologisch ansetzende Therapie. <b>2015</b> , 267-359		
162	Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis. <b>2015</b> , 67, 940-6		36
161	Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. <b>2015</b> , 14, 208-23		157
160	Multifocal VEP assessment of optic neuritis evolution. <b>2015</b> , 126, 1617-23		21
159	Alemtuzumab in multiple sclerosis: an update. <b>2015</b> , 5, 225-32		4
158	Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study. <i>Journal of Neurology</i> , <b>2015</b> , 262, 1024-34	5.5	20
157	Animal models of Multiple Sclerosis. <b>2015</b> , 759, 182-91		160
156	Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. <b>2015</b> , 29, 759-71		14
155	Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. <b>2015</b> , 86, 208-15		164
154	Alemtuzumab (Campath-1H). <b>2016</b> , 235-244		
153	A study of patients with aggressive multiple sclerosis at disease onset. <b>2016</b> , 12, 1907-12		9
152	Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations. <b>2016</b> , 10, 3379-3386		6
151	CAMPATH-1H: a tale of much patience and many patients. <b>2016</b> , 17, S15-S15		

150	Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. <b>2016</b> , 1,		19
149	Induction of Immunological Tolerance as a Therapeutic Procedure. <b>2016</b> , 4,		1
148	ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. <b>2016</b> , 16, 34		11
147	Prognostic factors associated with long-term disability and secondary progression in patients with Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 8, 27-34	4	16
146	Sustained reduction of MS disability: New player in comparing disease-modifying treatments. <b>2016</b> , 87, 1966-1967		2
145	The future of multiple sclerosis treatments. <b>2016</b> , 16, 1341-1356		6
144	Alemtuzumab for Multiple Sclerosis. <b>2016</b> , 16, 84		37
143	Myeloid cells - targets of medication in multiple sclerosis. <b>2016</b> , 12, 539-51		101
142	Management of multiple sclerosis in daily practice for general neurologist and healthcare professionals. <b>2016</b> , 7, 83-89		
141	Disease-modifying treatments for multiple sclerosis - a review of approved medications. <b>2016</b> , 23 Suppl 1, 18-27		182
140	Disease modifying therapies for relapsing multiple sclerosis. <b>2016</b> , 354, i3518		109
139	Inflammation: the Common Link in Brain Pathologies. <b>2016</b> ,		1
138	Alemtuzumab for multiple sclerosis. <b>2016</b> , 4, CD011203		15
137	Mechanisms of immunological tolerance. <b>2016</b> , 49, 324-8		13
136	Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. <b>2016</b> , 15, 259-69		129
135	Epidemiology of multiple sclerosis. <b>2016</b> , 172, 3-13		190
134	Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. <b>2016</b> , 13, 4-19		17
133	Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1235-41	5	14

132	Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. <b>2016</b> , 13, 58-69		59
131	Optimizing treatment success in multiple sclerosis. <i>Journal of Neurology</i> , <b>2016</b> , 263, 1053-65	5.5	111
130	The role of MRI in the evaluation of secondary progressive multiple sclerosis. <b>2016</b> , 16, 157-71		5
129	Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1215-23	5	68
128	Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2016</b> , 9, 31-43	6.6	22
127	Small molecules with anti-inflammatory properties in clinical development. <b>2016</b> , 157, 163-87		37
126	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. <i>Multiple Sclerosis and Related Disorders</i> , <b>2017</b> , 12, 70-78	4	64
125	Nogo-A Antibodies for Progressive Multiple Sclerosis. <b>2017</b> , 31, 187-198		24
124	Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment. <b>2017</b> , 303, 22-30		15
123	Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis. <b>2017</b> , 17, 611-629		5
122	Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy. <b>2017</b> , 308, 30-42		44
121	Mechanism of action of three newly registered drugs for multiple sclerosis treatment. <b>2017</b> , 69, 702-708		17
120	Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis. <b>2017</b> , 77, 885-910		16
119	FLAIR* to visualize veins in white matter lesions: A new tool for the diagnosis of multiple sclerosis?. <b>2017</b> , 27, 4257-4263		32
118	Multiple sclerosis: Pathology, diagnosis and treatments. <b>2017</b> , 13, 3163-3166		107
117	Immunomodulatory Therapy for Multiple Sclerosis. <b>2017</b> , 713-736		
116	High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. <b>2017</b> , 6, 145-152		20
115	Efficiency of antibody therapy in demyelinating diseases. <b>2017</b> , 29, 327-335		14

114	Multiple Sclerosis: Basic and Clinical. <b>2017</b> , 15, 211-252		4
113	Basement membranes and autoimmune diseases. <b>2017</b> , 57-58, 149-168		17
112	Safety concerns and risk management of multiple sclerosis therapies. <b>2017</b> , 136, 168-186		47
111	Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. <b>2017</b> , 7, 31-45		4
110	Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity-Report of a Case and Review of the Literature. <b>2017</b> , 8, 569		19
109	Sex Differences in Autoimmune Diseases. <b>2017</b> , 445-472		
108	Alemtuzumab as Treatment for Multiple Sclerosis. <b>2018</b> , 8,		9
107	Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?. <b>2018</b> , 89, 844-850		62
106	Disease-Modifying Treatment in Progressive Multiple Sclerosis. <b>2018</b> , 20, 12		39
105	Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus. <b>2018</b> , 118, 143-151		7
104	Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 919-931	5	25
103	CASE REPORT: New-Onset Autoimmune Thyrotoxicosis with Alemtuzumab Therapy Followed by Rapid Development of Hypothyroidism. <b>2018</b> , 30, 581-584		
102	A Pilot Investigation of Natural Killer Cell Function and Phenotypes in Stable and Active Multiple Sclerosis Patients. <b>2018</b> , 05,		
101	Goodpasture's Syndrome Following Alemtuzumab Therapy in Multiple Sclerosis. <b>2018</b> , 45, 712-714		3
100	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , <b>2018</b> , 265, 2851-2860	5.5	24
99	Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years. <b>2018</b> , 28, 1682-1693		11
98	Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. <b>2018</b> , 76, 539-554		13
97	Induction or escalation therapy for patients with multiple sclerosis?. <b>2018</b> , 174, 449-457		9

96	The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. <b>2018</b> , 90, e2107-e2118		51
95	T Lymphocytes and Autoimmunity. <b>2018</b> , 341, 125-168		37
94	Anti-mouse CD52 Treatment Ameliorates Colitis through Suppressing Th1/17 Mediated Inflammation and Promoting Tregs Differentiation in IL-10 Deficient Mice. <b>2018</b> , 41, 1423-1429		2
93	New biological agents in the treatment of multiple sclerosis. <b>2018</b> , 119, 191-197		5
92	Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective. <b>2018</b> , 18, 21-31		1
91	Multiple Sclerosis. <b>2019</b> , 891-902.e1		1
90	General Principles of Immunotherapy in Neurological Diseases. <b>2019</b> , 387-421		1
89	Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. <b>2019</b> , 404, 19-28		7
88	Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model. <b>2019</b> , 6, 1362-1372		4
87	2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. <b>2019</b> , 8, 173-185		20
86	Immunological Aspects of Approved MS Therapeutics. <b>2019</b> , 10, 1564		74
85	Predicting functional recovery after mild traumatic brain injury: the SHEFBIT cohort. <b>2019</b> , 33, 1158-1164		10
84	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1273-1288	5	23
83	Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis. <b>2019</b> , 33, 2058738419843690		5
82	Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. <b>2019</b> , 76, 536-541		90
81	Scf̄ose en plaques : les nouvelles approches physiopathologiques. <b>2019</b> , 10, 112-117		
80	Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model. <b>2019</b> , 328, 78-85		3
79	Multiple sclerosis - a review. <b>2019</b> , 26, 27-40		422

78	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1093-1101	5	5
77	Biologic therapy in the idiopathic inflammatory myopathies. <b>2020</b> , 40, 191-205		4
76	CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis. <b>2020</b> , 11, 2040622320947378		2
75	Multiple sclerosis. <b>2020</b> , 271-300		
74	Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. <b>2020</b> , 7,		16
73	Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. <b>2020</b> , 17, 189		17
72	Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status. <b>2020</b> , 34, 307-325		7
71	Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 40, 101956	4	6
70	New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-Associated Vasculitis. <b>2021</b> , 73, 361-370		5
69	Promoting remyelination in multiple sclerosis. <i>Journal of Neurology</i> , <b>2021</b> , 268, 30-44	5.5	34
68	Emerging potential of cannabidiol in reversing proteinopathies. <b>2021</b> , 65, 101209		11
67	Living with secondary progressive multiple sclerosis in Europe: perspectives of multiple stakeholders. <b>2021</b> , 11, 9-19		2
66	Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. <b>2021</b> , 9,		15
65	Monoclonal Antibodies as Neurological Therapeutics. <b>2021</b> , 14,		12
64	Translational Aspects of Immunotherapeutic Targets in Multiple Sclerosis. <b>2021</b> , 287-301		
63	Multiple Sclerosis Phenotypes as a Continuum: The Role of Neurologic Reserve. <b>2021</b> , 11, 342-351		4
62	Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives. <b>2021</b> , 18, 244-251		5
61	Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis. <b>2021</b> , 421, 117324		0

60 Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis. **2021**, 13, e13246

59 Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry. *Multiple Sclerosis Journal*, **2021**, 27, 2254-2266 5 4

58 A review: Pathophysiology, diagnosis and management of multiple sclerosis. **2021**, 8, 16-18

57 Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era. **2021**, 10, 237-246 0

56 Reaching the limit of modern highly active immune modulating agents in a female patient with relapsing-remitting multiple sclerosis. *Neuroimmunology Reports*, **2021**, 1, 100009

55 Recurrence and Prognostic Value of Asymptomatic Spinal Cord Lesions in Multiple Sclerosis. *Journal of Clinical Medicine*, **2021**, 10, 5.1 0

54 Deimination in Multiple Sclerosis: The Bad, the Good, and the Ugly. **2017**, 317-336 1

53 Conduction studies in multiple sclerosis. 1-7 1

52 IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). **2009**, 119, 2052-61 215

51 The adaptive immune system in diseases of the central nervous system. **2012**, 122, 1172-9 62

50 Severe, Highly Active, or Aggressive Multiple Sclerosis. **2016**, 22, 761-84 11

49 An Investigation for Enhancing Registration Performance with Brain Atlas by Novel Image Inpainting Technique using Dice and Jaccard Score on Multiple Sclerosis (MS) Tissue. **2019**, 12, 1249-1262 4

48 [Clinical recommendations on the use of alemtuzumab (lemturada)]. **2017**, 117, 115-126 3

47 Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. **2020**, 9, 6

46 Multiple sclerosis--new treatment modalities. **2015**, 142, 647-54 2

45 Multiple sclerosis. **2019**, 9, 349-358 7

44 Cannabinoids for the Control of multiple Sclerosis. **2008**, 375-394

43 Sclerosi multipla e varianti. **2009**, 101-129

- 42 Management of Aggressive Multiple Sclerosis: Options and Challenges. **2010**, 35, 304-315
- 41 Disease Modifying Agents in the Treatment of Multiple Sclerosis. **2011**, 131-156
- 40 Mechanisms of Disease Progression. **2013**, 71-92
- 39 Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies. **2013**, 187-219
- 38 Farmaci che influenzano l'andamento della malattia. **2013**, 27-40
- 37 Alemtuzumab: A Place in Therapy for Treatment of Multiple Sclerosis. *International Journal of Clinical Medicine*, **2013**, 04, 459-471 0.3
- 36 Targeting CD52 for the Treatment of Multiple Sclerosis. **2013**, 385-399
- 35 Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role. *International Journal of MS Care*, **2013**, 15, 159-68 2.3 1
- 34 Demyelinating Diseases and Neuroinflammation. **2016**, 139-170
- 33 Induction of Immunological Tolerance as a Therapeutic Procedure. 771-785
- 32 Mechanisms of Disease Progression. **2018**, 71-92
- 31 Monoclonal Antibody Therapy and Long-term Outcomes in Multiple Sclerosis [The Challenge of Treatment Optimisation. *European Neurological Review*, **2018**, 13, 78 0.5
- 30 Cell Therapy: A Therapeutic Option for Multiple Sclerosis. *The Neuroscience Journal of Shefaye Khatam*, **2018**, 6, 52-68 0.1 2
- 29 Multiple Sklerose: Therapie. *Springer Reference Medizin*, **2019**, 1-25 0
- 28 Drugs for Soft Tissue Autoimmune Disorders. **2019**, 751-775
- 27 Alemtuzumab Associated Listeria Monocytogenes Meningitis. *Journal of Contemporary Pharmacy Practice*, **2019**, 66, 45-49 0.1
- 26 The evolution of therapeutic antibodies. **2020**, 296-298
- 25 Alemtuzumab Induction Is Associated With Equalization of Graft Outcomes Between Elderly and Nonelderly Kidney Transplant Recipients: A Single-Center Report. *Experimental and Clinical Transplantation*, **2020**, 18, 284-291 0.8



24	VEGF and TNF- $\beta$ Responses to Acute and Chronic Aerobic Exercise in the Patients with Multiple Sclerosis. <i>Asian Journal of Sports Medicine</i> , <b>2020</b> , 11,	1.4	1
23	Multiple Sklerose: Therapie. <i>Springer Reference Medizin</i> , <b>2020</b> , 1099-1123	0	
22	Literatur. <b>2022</b> , 468-512		
21	Immune reconstitution, glomerulonephritis, and successful treatment with rituximab. <i>Clinical Nephrology Case Studies</i> , <b>2020</b> , 8, 67-71	1.3	
20	Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. <i>Journal of Clinical &amp; Cellular Immunology</i> , <b>2013</b> , 4,	2.7	28
19	Hepatitis B and C prophylaxis in patients receiving chemotherapy. <b>2014</b> , 6, 10-13		3
18	Aptamer-nanoconjugates as emerging theranostic systems in neurodegenerative disorders. <i>Colloids and Interface Science Communications</i> , <b>2022</b> , 46, 100554	5.4	1
17	Smouldering multiple sclerosis: the 'real MS'.. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2022</b> , 15, 17562864211066751	6.6	5
16	Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives.. <i>Biology</i> , <b>2022</b> , 11,	4.9	7
15	S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 59, 103681	4	2
14	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature.. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11,	5.1	0
13	Time course of lesion-induced atrophy in multiple sclerosis.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	0
12	Early switch from cladribine to alemtuzumab in highly-active relapsing-remitting multiple sclerosis: A case report. <i>Neuroimmunology Reports</i> , <b>2022</b> , 2, 100095		
11	Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585221089534	5	0
10	Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> ,	5.5	
9	Grey matter atrophy in patients with benign multiple sclerosis. <i>Brain and Behavior</i> ,	3.4	0
8	Graves' disease following commencement of alemtuzumab therapy: Case report discussing clinical considerations and possible pathophysiology. <b>2022</b> , 25, 100120		0
7	The sequential natalizumab $\rightarrow$ alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial [Part I: Rationale and objectives. <b>2022</b> , 14, 117957352211239		0

- 6 Multi-modal retinal scanning to measure retinal thickness and peripheral blood vessels in multiple sclerosis. **2022**, 12, 0
- 5 Brain modulation by the gut microbiota: From disease to therapy. **2022**, 1
- 4 Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. 0
- 3 In Silico Drug Repurposing in Multiple Sclerosis Using scRNA-Seq Data. **2023**, 24, 985 0
- 2 Sex hormone therapy in multiple sclerosis: a systematic review of clinical trials. 0
- 1 Multiple Sclerosis. **2023**, 843-853 0